Published in Biotech Law Weekly, April 27th, 2007
"Acceptance to ASCO provides CytImmune the opportunity to present its research to the leading body of international oncology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.